Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | TXK | P42681 | 1/20 | 0.33 |
| ▸ | BLK | P51451 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206650 | 0.93 | LRRK2 (0.36) | JAK3JAK1EGFRJAK2TTK | |
| SCHEMBL10206652 | 0.92 | LRRK2 (0.38) | JAK3NTRK1EGFRJAK2LRRK2 | |
| SCHEMBL10206649 | 0.90 | NTRK1 (0.36) | JAK3NTRK1JAK1EGFRJAK2 | |
| SCHEMBL10207051 | 0.89 | NTRK1 (0.37) | JAK3NTRK1JAK1EGFRJAK2 | |
| SCHEMBL16255590 | 0.88 | JAK3 (0.36) | JAK3JAK1EGFRJAK2TTK | |
| SCHEMBL10206630 | 0.87 | JAK3 (0.37) | JAK3NTRK1JAK1EGFRJAK2 | |
| SCHEMBL10206187 | 0.86 | EGFR (0.45) | JAK3JAK1EGFRJAK2TTK | |
| SCHEMBL10205875 | 0.85 | LRRK2 (0.39) | JAK3NTRK1EGFRJAK2LRRK2 | |
| SCHEMBL10205075 | 0.84 | STK17A (0.40) | JAK3NTRK1JAK1EGFRJAK2 | |
| SCHEMBL10206623 | 0.83 | JAK3 (0.37) | JAK3JAK1EGFRJAK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655358-B1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8546443-B2 | Benzylic oxindole pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012085126-A1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | MKI67, CCNI, CCNB1 | JAK3 1636/4885NTRK1 2690/4885JAK1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.